Analyst Josh Jennings from TD Cowen maintained a Hold rating on Edwards Lifesciences (EW – Research Report) and keeping the price target at ...

Edwards Lifesciences (EW) announced one-year data highlighting the continued performance of its SAPIEN 3 Ultra RESILIA valve. The data were ...

Edwards Lifesciences (NYSE:EW) today announced one-year data highlighting strong performance from its Sapien 3 Ultra Resilia ...

Designed for patients needing a replacement valve, the company’s TAVI trial has found low rates of mortality after a year of ...

JPMorgan keeps an Overweight rating on Edwards Lifesciences (EW) after the company reported results from the EARLY TAVR trial, the first of its kind studying Sapien 3 in asymptomatic severe aortic ...

The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. Edwards Lifesciences (NYSE ...

Class Action Lawsuit Against Edwards Lifesciences Corporation (EW): The litigation is focused on the propriety of Edwards Lifesciences’ disclosures about its core product, the Transcatheter Aort ...

NEW YORK, NY / ACCESSWIRE / November 19, 2024 / Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Edwards Lifesciences Corporation (NYSE:EW) and ...

If you wish to serve as lead plaintiff of the Edwards Lifesciences lawsuit ... the Company's growth was at risk of decelerating; (3) the Company's "patient activation activities" failed to ...

If you invested in Edwards Lifesciences, you are encouraged to obtain additional information by visiting . Investors have until December 13, 2024 to ask the Court to be appointed to lead the case.

presented during the lat JPMorgan keeps an Overweight rating on Edwards Lifesciences (EW) after the company reported results from the EARLY TAVR trial, the first of its kind studying Sapien 3 in ...